The Sahlgrenska Anti-VEGF Study

Overview

The study investigates whether patients treated for neovascular (wet) age-related macular degeneration (AMD), with intravitreal injection with bevacizumab (Avastin) after two years need more injections with retained therapy response compared to patients being treated with intravitreal injection with aflibercept (Eylea).

The study also aims to evaluate if there is a difference in best-corrected visual acuity, macular thickness, recurrence interval, durability, cost efficiency, as well as vision-related quality of life.

Full Title of Study: “The Sahlgrenska Anti-VEGF (SAHLVE) Study – a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2023

Interventions

  • Drug: Bevacizumab Injection
    • 25 mg/ml
  • Drug: Aflibercept Injection
    • 40 mg/ml

Arms, Groups and Cohorts

  • Experimental: Avastin
    • bevacizumab 25 mg/ml, intravitreal administration, 0.05 ml (1.25 mg)
  • Active Comparator: Eylea
    • aflibercept 40 mg/ml, intravitreal administration, 0.05 ml (2 mg)

Clinical Trial Outcome Measures

Primary Measures

  • Number of injections
    • Time Frame: Two years
    • Number of intravitreal injections

Secondary Measures

  • Best-corrected visual acuity (BCVA), distance
    • Time Frame: Two years
    • ETDRS
  • Best-corrected visual acuity (BCVA), near
    • Time Frame: Two years
    • LIX
  • Macular thickness (Central Retinal Thickness; CRT)
    • Time Frame: Two years
    • μm
  • Intraocular pressure (IOP)
    • Time Frame: Two years
    • mmHg
  • Recurrence interval
    • Time Frame: Two years
    • Maximum number of weeks from last injection to relapse, at first and last relapse.
  • Durability
    • Time Frame: Two years
    • Longest inactive interval detected (number of weeks).
  • Cost efficiency
    • Time Frame: Two years
    • Quality-adjusted life years (QALY), cost-per-QALY is measured with the EuroQol-5 Dimension (EQ-5D) questionnaire. EQ-5D consists of five subscales: mobility, self-care, usual activities, discomfort/pain and anxiety/depression. The subscales measure different aspects of health and well-being where the subject is asked to rank each subscale from 1 (no problems) to 3 (major problems). These answers are converted to a score between 0 (=death) to 1 (=full health). The subscales are converted to a weighted mean which ranges from 0 (death) to 1 (full health). Negative values may exists for conditions worse than death. The weighting differs between geographic areas; for Sweden, the UK weighting scale is used.
  • Vision-related quality of life
    • Time Frame: Two years
    • National Eye Institute Visual Functioning Questionnaire -25 (NEI VFQ-25) questionnaire is based on 25 questions (items) where the subject is asked questions on visual function, daily activities and social consequences of visual function. The questions have answers on a 5- or 6-grade scale which are converted to a scale from 0 (no function/worst consequence) to 100 (no problems). The 25 items are clustered into 12 subscales. Items within each subscale are averaged to create the subscale scores according to the NEI VFQ-25 scoring algorithm. In addition, a composite score for all 12 subscales are created as an average of these. Minimum score is 0 and maximum score is 100 for each item, subscale and the composite score.
  • Cost-benefit
    • Time Frame: Two years
    • The incremental cost-effectiveness ratio (ICER) is a statistic used in cost-effectiveness analysis to summarise the cost-effectiveness of a health care intervention. It represents the average incremental cost associated with 1 additional unit of the measure of effect and is given in Euro.

Participating in This Clinical Trial

Inclusion Criteria

Signed informed consent.

≥50 years, regardless of gender.

Diagnosed with the neovascular (wet) form of age-related macular degeneration through diagnosed neovascular vascular membranes with OCT-A and, if necessary, also FA / ICG, according to clinical routine.

Distance visual acuity ≥34 (ETDRS) on the current study eye.

Exclusion Criteria

Other eye disease in the current study eye that affects visual acuity or the possibility of examining fundus, according to the investigator's assessment.

Previously received treatment for the neovascular (wet) form of age-related macular degeneration.

Diagnosed with diabetes (all types).

Degenerative state of the macula that prevents vision improvement such as central areolar atrophy or other pronounced dry AMD or fibrosis, in the current study eye.

Other choroidal neovascularization (CNV) of the type PCV or due to grave myopia i.e. ≥ 6.0 diopters (D) or secondary to other retinal disease, in the current study eye.

Unregulated intraocular pressure (IOP) > 30 mmHg despite pharmacological treatment in the current study eye.

Have had a stroke or heart attack ≤6 months ago.

Inability to access information (e.g. due to dementia) or inability to conduct examinations (e.g. ETDRS examination), according to the investigator's assessment.

Inability to receive oral and written information in Swedish (in need of an interpreter).

Included in another intervention study.

Fertile woman i.e. a woman who has had menstruation for the past 12 months or has not undergone permanent sterilization (hysterectomy, bilateral salpingectomy or bilateral oophorectomy).

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Vastra Gotaland Region
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Madeleine Zetterberg, MD, PhD, Principal Investigator, Vastra Gotaland Region
  • Overall Contact(s)
    • Madeleine Zetteberg, MD, PhD, +46 (0)31-3433255, madeleine.zetterberg@vgregion.se

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.